Brain Cancer Clinical Trial
Official title:
An Open-Label Study of the Efficacy of 18F-FSPG PET/CT in Subjects With Intracranial Cancers
The aim of this study is to explore the efficacy of 18F-FSPG in the detection of primary or metastatic brain cancer lesions confirmed by a standard of truth, preferably histology. This is a single center, open labelled, non-randomized study. A total of 30 subjects with brain tumor or brain metastases will be enrolled. All different stages of malignancies will be recruited, including those with different types of pathologies and grades, and newly diagnosed or recurrent disease.
Subjects with various types and grades of primary brain tumors or brain metastasis will be
recruited. The brain tumor needs to be either histologically or clinically confirmed.
18F-FSPG will be injected intravenously into the subjects, and PET/CT imaging performed.
Images will be assessed visually and quantitatively.
Available tumor specimens will be analyzed by immunohistochemistry (IHC) for example for
expression of components of the system xc- and associated biomarkers.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05023434 -
A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors
|
||
Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
Completed |
NCT04114786 -
3D Printed Mask for GBM and Brain Mets
|
N/A | |
Recruiting |
NCT04367779 -
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
|
||
Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
Completed |
NCT02852655 -
A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
|
Phase 1 | |
Completed |
NCT02911155 -
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
|
||
Completed |
NCT01650922 -
Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples
|
N/A | |
Completed |
NCT00329589 -
A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients
|
Phase 1 | |
Completed |
NCT00505141 -
Urban Environmental Exposures and Childhood Cancer
|
N/A | |
Completed |
NCT00504660 -
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
|
Phase 2 | |
Completed |
NCT00979810 -
Image-Guided Stereotactic Biopsy of High Grade Gliomas
|
N/A | |
Recruiting |
NCT04899908 -
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
|
Phase 2 | |
Active, not recruiting |
NCT02851706 -
Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
|
||
Completed |
NCT02798406 -
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
|
Phase 2 | |
Completed |
NCT01012609 -
External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas
|
Phase 2 | |
Completed |
NCT00782756 -
Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
|
Phase 2 | |
Terminated |
NCT03149575 -
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
|
Phase 3 | |
Completed |
NCT01974804 -
Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis
|
||
Withdrawn |
NCT01320787 -
18-F-Fluoroacetate as PET Imaging Agent
|
Phase 1 |